Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACOG Alpha Cognition	$9.16 +2.5%	$7.62	$3.75 ▼ $11.40	$146.74M	2.78	101,600 shs	79,760 shs
LXEO Lexeo Therapeutics	$3.91 -7.8%	$3.36	$1.45 ▼ $19.50	$129.80M	0.52	528,171 shs	756,031 shs
LYEL Lyell Immunopharma	$8.69 -9.3%	$9.10	$7.65 ▼ $45.42	$128.70M	-0.26	69,045 shs	229,031 shs
RNTX Rein Therapeutics	$1.54 -6.1%	$1.87	$1.35 ▼ $4.40	$34.11M	1.3	32,369 shs	104,765 shs

13 Stocks Institutional Investors Won't Stop Buying

Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACOG Alpha Cognition	0.00%	-2.03%	+0.22%	+71.86%	+915,999,900.00%
LXEO Lexeo Therapeutics	0.00%	-0.76%	+38.65%	-4.40%	-75.86%
LYEL Lyell Immunopharma	0.00%	-10.78%	+3.92%	-22.30%	-78.80%
RNTX Rein Therapeutics	0.00%	-18.09%	-24.88%	-20.21%	+153,999,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ACOG Alpha Cognition	1.7802 of 5 stars	3.5	0.0	0.0	0.0	2.9	0.8	0.0
LXEO Lexeo Therapeutics	1.9019 of 5 stars	3.5	2.0	0.0	0.0	0.0	2.5	0.6
LYEL Lyell Immunopharma	2.9564 of 5 stars	2.8	3.0	0.0	0.0	1.1	5.0	1.3
RNTX Rein Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACOG Alpha Cognition	3.00	Buy	$20.00	118.34% Upside
LXEO Lexeo Therapeutics	3.00	Buy	$16.60	324.55% Upside
LYEL Lyell Immunopharma	1.50	Reduce	$20.00	130.15% Upside
RNTX Rein Therapeutics	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest RNTX, ACOG, LYEL, and LXEO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/30/2025	LXEO Lexeo Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$16.00 ➝ $10.00
5/16/2025	ACOG Alpha Cognition	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00 ➝ $20.00
5/16/2025	LXEO Lexeo Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$23.00 ➝ $15.00
5/13/2025	LXEO Lexeo Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$22.00 ➝ $20.00
4/16/2025	LYEL Lyell Immunopharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$20.00 ➝ $20.00
4/8/2025	LXEO Lexeo Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$25.00 ➝ $22.00
4/8/2025	LXEO Lexeo Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$23.00 ➝ $23.00
3/31/2025	ACOG Alpha Cognition	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00 ➝ $20.00
3/26/2025	LXEO Lexeo Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$23.00 ➝ $23.00
3/25/2025	ACOG Alpha Cognition	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Moderate Buy
3/25/2025	LXEO Lexeo Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$24.00 ➝ $20.00

(Data available from 6/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACOG Alpha Cognition	N/A	N/A	N/A	N/A	$2.59 per share	N/A
LXEO Lexeo Therapeutics	$650K	199.69	N/A	N/A	$3.53 per share	1.11
LYEL Lyell Immunopharma	$60K	2,144.98	N/A	N/A	$26.21 per share	0.33
RNTX Rein Therapeutics	N/A	N/A	$0.45 per share	3.44	$0.43 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACOG Alpha Cognition	-$14.64M	-$1.20	N/A	∞	N/A	N/A	-65.83%	-48.21%	8/11/2025 (Estimated)
LXEO Lexeo Therapeutics	-$98.33M	-$3.30	N/A	N/A	N/A	N/A	-85.86%	-68.48%	8/11/2025 (Estimated)
LYEL Lyell Immunopharma	-$342.99M	-$25.00	N/A	N/A	N/A	-514,649.22%	-73.66%	-60.99%	8/6/2025 (Estimated)
RNTX Rein Therapeutics	-$62.88M	-$2.86	N/A	N/A	N/A	N/A	-86.07%	-31.11%	N/A

Latest RNTX, ACOG, LYEL, and LXEO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2025	Q1 2025	ACOG Alpha Cognition	-$0.58	-$0.20	+$0.38	-$0.13	$0.50 million	$2.93 million
5/15/2025	Q1 2025	RNTX Rein Therapeutics	-$0.21	-$0.25	-$0.04	-$0.25	N/A	N/A
5/13/2025	Q1 2025	LYEL Lyell Immunopharma	-$3.80	-$3.60	+$0.20	-$0.18	N/A	$0.01 million
5/12/2025	Q1 2025	LXEO Lexeo Therapeutics	-$0.80	-$0.99	-$0.19	-$0.99	N/A	N/A
4/7/2025	Q4 2024	RNTX Rein Therapeutics	N/A	-$0.26	N/A	-$1.89	N/A	N/A
3/31/2025	Q4 2024	ACOG Alpha Cognition	-$0.48	-$0.51	-$0.03	-$0.51	N/A	N/A
3/24/2025	Q4 2024	LXEO Lexeo Therapeutics	-$0.87	-$0.78	+$0.09	-$0.78	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACOG Alpha Cognition	N/A	N/A	N/A	N/A	N/A
LXEO Lexeo Therapeutics	N/A	N/A	N/A	N/A	N/A
LYEL Lyell Immunopharma	N/A	N/A	N/A	N/A	N/A
RNTX Rein Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACOG Alpha Cognition	N/A	17.14	16.83
LXEO Lexeo Therapeutics	0.01	3.42	3.42
LYEL Lyell Immunopharma	N/A	7.49	7.49
RNTX Rein Therapeutics	N/A	1.39	1.39

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACOG Alpha Cognition	N/A
LXEO Lexeo Therapeutics	60.67%
LYEL Lyell Immunopharma	66.05%
RNTX Rein Therapeutics	90.89%

Insider Ownership

Company	Insider Ownership
ACOG Alpha Cognition	14.00%
LXEO Lexeo Therapeutics	5.30%
LYEL Lyell Immunopharma	22.30%
RNTX Rein Therapeutics	5.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACOG Alpha Cognition	N/A	16.02 million	13.78 million	N/A
LXEO Lexeo Therapeutics	58	33.20 million	31.44 million	Not Optionable
LYEL Lyell Immunopharma	270	14.81 million	11.51 million	Optionable
RNTX Rein Therapeutics	9	22.15 million	21.02 million	N/A

RNTX, ACOG, LYEL, and LXEO Headlines

Recent News About These Companies

Financial Survey: Rein Therapeutics (RNTX) & Its Rivals

June 13, 2025 | americanbankingnews.com

US FDA puts on hold Rein Therapeutics' lung disease drug trial

June 12, 2025 | reuters.com

RNTX Rein Therapeutics Inc.

June 1, 2025 | seekingalpha.com

Rein Therapeutics, Inc.: Rein Therapeutics Announces First Patient Dosed in RENEW Phase 2 Trial of LTI-03 in Patients with IPF

May 28, 2025 | finanznachrichten.de

Rein Therapeutics Announces First Patient Dosed in RENEW Phase 2 Trial of LTI-03 in Patients with IPF

May 27, 2025 | prnewswire.com

Rein Therapeutics Presents Two Posters at the American Thoracic Society 2025 International Conference

May 19, 2025 | prnewswire.com

Rein Therapeutics, Inc.: Rein Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

May 16, 2025 | finanznachrichten.de

Rein Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

May 15, 2025 | prnewswire.com

Rein Therapeutics begins trial for idiopathic pulmonary fibrosis treatment

May 13, 2025 | msn.com

Rein Therapeutics, Inc.: Rein Therapeutics Announces Initiation of RENEW Phase 2 Trial of LTI-03 in Patients with IPF

May 12, 2025 | finanznachrichten.de

Rein Therapeutics Announces Initiation of RENEW Phase 2 Trial of LTI-03 in Patients with IPF

May 12, 2025 | prnewswire.com

Rein Therapeutics to integrate Qureight’s platform in trial of IPF treatment

May 2, 2025 | msn.com

Rein Therapeutics and Qureight Ltd Announce Planned Integration of Deep-Learning Platform for Phase 2 Trial of LTI-03 in Patients with IPF

May 1, 2025 | prnewswire.com

Rein Therapeutics to Present at The Citizens Life Sciences Conference 2025

April 30, 2025 | prnewswire.com

Rein Therapeutics Announces Abstract Accepted for Presentation at the American Thoracic Society 2025 International Conference

April 28, 2025 | prnewswire.com

Rein Therapeutics Granted Two Patents Covering the Novel Formulation and Administration Methods of Dry Powder LTI-03 for the Treatment of Respiratory Diseases

April 23, 2025 | prnewswire.com

Rein Therapeutics reports IPF and PASC-F treatment progress

April 18, 2025 | uk.investing.com

Rein Therapeutics’ LTI-2355 peptide shows therapuetic potential in study

April 16, 2025 | markets.businessinsider.com

Rein Therapeutics Announces a Publication in Biomedicines on the Immunomodulatory and Anti-fibrotic Properties of a Caveolin-1-Related Peptide in IPF and PASC-F

April 15, 2025 | prnewswire.com

Rein Therapeutics, Inc.: Rein Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

April 8, 2025 | finanznachrichten.de

New MarketBeat Followers Over Time

Media Sentiment Over Time

RNTX, ACOG, LYEL, and LXEO Company Descriptions

Alpha Cognition NASDAQ:ACOG

$9.16 +0.22 (+2.46%)

As of 06/20/2025 04:00 PM Eastern

Alpha Cognition, Inc. is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer's Dementia and Amyotrophic Lateral Sclerosis. The company was founded in 2000 and is headquartered in Vancouver, Canada.

Lexeo Therapeutics NASDAQ:LXEO

$3.91 -0.33 (-7.78%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$3.89 -0.02 (-0.51%)

As of 07:08 AM Eastern

Lexeo Therapeutics, Inc. operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York.

Lyell Immunopharma NASDAQ:LYEL

$8.69 -0.89 (-9.29%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$9.10 +0.41 (+4.72%)

As of 06/20/2025 06:03 PM Eastern

Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic. It is also developing LYL797, a genetically and epigenetically reprogrammed ROR1 chimeric antigen receptor (CAR) T cell product candidate that is in Phase 1 clinical trial for the treatment of various solid tumors; and LYL845, a novel epigenetically reprogrammed tumor-infiltrating lymphocytes product candidate, which is in Phase 1 clinical trial targeting multiple solid tumor indications. In addition, the company's preclinical product candidates include LYL119, a ROR1 CAR T-cell product for the treatment of enhanced cytotoxicity; and second generation TIL product. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

Rein Therapeutics NASDAQ:RNTX

$1.54 -0.10 (-6.10%)

As of 06/20/2025 04:00 PM Eastern

Rein Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of a novel class of therapeutics for the treatment of cancer and other diseases. It focuses on its lead product candidate, ALRN-6924, which is a cell-permeating peptide that disrupts the interaction of p53 suppressors MDM2 and MDMX with tumor suppressor p53 to reactivate tumor suppression in non-mutant, or wild-type, p53 cancers. The company was founded by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky on August 6, 2001 and is headquartered in Austin, TX.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time